

RCL Antibody (N-term) Blocking peptide Synthetic peptide Catalog # BP5930a

## Specification

# **RCL Antibody (N-term) Blocking peptide - Product Information**

Primary Accession Other Accession <u>O43598</u> <u>NP\_006434.1, NP\_954653.1</u>

## **RCL Antibody (N-term) Blocking peptide - Additional Information**

Gene ID 10591

**Other Names** 

2'-deoxynucleoside 5'-phosphate N-hydrolase 1 {ECO:0000255|HAMAP-Rule:MF\_03036}, 322-{ECO:0000255|HAMAP-Rule:MF\_03036, ECO:0000269|PubMed:24260472, ECO:0000269|PubMed:25108359}, c-Myc-responsive protein RCL {ECO:0000255|HAMAP-Rule:MF\_03036}, DNPH1 {ECO:0000255|HAMAP-Rule:MF\_03036}

### Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **RCL Antibody (N-term) Blocking peptide - Protein Information**

Name DNPH1 (HGNC:21218)

Function

Part of a nucleotide salvage pathway that eliminates epigenetically modified 5-hydroxymethyl-dCMP (hmdCMP) in a two-step process entailing deamination to cytotoxic 5-hydroxymethyl-dUMP (hmdUMP), followed by its hydrolysis into 5-hydroxymethyluracil (hmU) and 2-deoxy-D-ribose 5-phosphate (deoxyribosephosphate) (PubMed:<a href="http://www.uniprot.org/citations/33833118" target="\_blank">33833118</a>). Catalyzes the second step in that pathway, the hydrolysis of the N-glycosidic bond in hmdUMP, degrading this cytotoxic nucleotide to avoid its genomic integration (PubMed:<a href="http://www.uniprot.org/citations/33833118" target="\_blank">33833118</a>).

Cellular Location Cytoplasm. Nucleus

**Tissue Location** Expressed at low levels in brain, colon, lung, peripheral blood leukocytes, placenta, small intestine,



and thymus Expressed at high levels in heart, kidney, liver, skeletal muscle and spleen. Overexpressed in a significant proportion of breast cancers

# **RCL Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

**RCL Antibody (N-term) Blocking peptide - Images**